These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11286542)

  • 1. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.
    Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M
    Clin Immunol; 2001 Apr; 99(1):65-74. PubMed ID: 11286542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
    Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
    Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
    Rini B; Wadhwa M; Bird C; Small E; Gaines-Das R; Thorpe R
    Cytokine; 2005 Jan; 29(2):56-66. PubMed ID: 15598439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF.
    Wadhwa M; Mellstedt H; Small E; Thorpe R
    Dev Biol (Basel); 2003; 112():61-7. PubMed ID: 12762505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.
    Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H
    Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of anti-tumor immunity by lyophilized myeloma cells secreting GM-CSF.
    Wu S; Yuan D; Liu JN; Tan XY
    Oncol Rep; 2007 Jan; 17(1):129-33. PubMed ID: 17143489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.
    Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R
    Clin Exp Immunol; 1996 May; 104(2):351-8. PubMed ID: 8625532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.
    Krinner EM; Raum T; Petsch S; Bruckmaier S; Schuster I; Petersen L; Cierpka R; Abebe D; Mølhøj M; Wolf A; Sørensen P; Locher M; Baeuerle PA; Hepp J
    Mol Immunol; 2007 Feb; 44(5):916-25. PubMed ID: 16697465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
    Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
    Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
    Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.
    Hjelm Skog AL; Wadhwa M; Hassan M; Gharizadeh B; Bird C; Ragnhammar P; Thorpe R; Mellstedt H
    Clin Cancer Res; 2001 May; 7(5):1163-70. PubMed ID: 11350880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
    J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ; Malya R; Rawat A
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.